( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...

The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...